GITNUXSOFTWARE ADVICE
Science ResearchTop 10 Best Real World Evidence Services of 2026
Editorial roundup comparing real world evidence services and where Certara, Optum, and Merative fit for pragmatic vendor shortlists.
How we ranked these tools
Vendors set the topic, but our editors set the inclusion criteria and the evaluation framework before research starts.
Agents extract product evidence with provenance, then collect written reviews and transcribe video reviews and podcasts.
Framework: Features 40% · Ease 30% · Value 30%
Gitnux may earn a commission through links on this page — this does not influence rankings. Editorial policy
Certara is the best pick for teams that need managed RWE execution across messy healthcare data, because its programmatic workflows turn messy sources into consistent, review-ready observational outputs with strong causal confounding control, while Analysis Group is a strong alternative for sponsors that want one team to carry cohort building through estimand and sensitivity interpretation.
Editor’s top 3 picks
Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.
Certara
Programmatic evidence production workflows that convert messy healthcare data into consistent, review-ready observational study outputs.
Best for: Fits when teams need managed RWE execution across multiple data sources with causal-method rigor.
Optum
Editor pickEvidence production that couples healthcare-linked data integration with protocol-driven cohort build and validation work products.
Best for: Fits when sponsors need governed, repeatable RWE production using claims plus clinical sources under tight execution controls.
Merative
Editor pickProject delivery includes structured provenance and dataset build controls tied to sponsor-facing study outputs.
Best for: Fits when sponsors need staffed RWE delivery with strong provenance, linkage, and governed outputs.
Comparison Table
Certara
enterprise_vendorDelivers RWE, pharmacoeconomics, health outcomes, and regulatory evidence services for drug developers.
Programmatic evidence production workflows that convert messy healthcare data into consistent, review-ready observational study outputs.
Certara runs real-world evidence programs that translate RWD into analysis-ready study datasets for regulatory-grade observational research. Its core delivery centers on data integration, cohort construction, and evidence production work that includes study design support for comparative effectiveness and causal methods.
Certara also offers technical services that wrap around clients’ data assets and governance processes, including repeatable study execution for retrospective and prospective-style workflows. Across engagements, Certara’s differentiator is the ability to operate across complex healthcare data sources and deliver consistent outputs for analysis and review cycles.
- +End-to-end study execution from data ingestion through analysis-ready cohorts
- +Strong support for causal confounding control methods used in comparative RWE
- +Proven capability to run evidence production across heterogeneous healthcare sources
- +Repeatable workflow design for multi-study program timelines
- –Requires clear client-side governance inputs to avoid schedule drag
- –Integration scope can expand materially when data provenance and transformations are unclear
- –Automation depth depends on the client’s initial data readiness and formats
- –Operational cadence can feel heavy for small, single-study requests
Biostatistics and epidemiology teams
Build analysis datasets from RWD
Defensible analysis dataset
Regulatory and medical writers
Turn study evidence into documents
Consistent evidence documents
Show 2 more scenarios
Quantitative pharmacology teams
Model dose and exposure decisions
Structured development evidence
Applies pharmacometric and biosimulation workflows that structure real world evidence for development decisions.
Pharmacovigilance teams
Produce recurring safety reports
Repeatable safety reporting
Reconciles safety inputs and runs controlled workflows for repeated real world evidence safety reporting.
Best for: Fits when teams need managed RWE execution across multiple data sources with causal-method rigor.
Optum
enterprise_vendorProvides healthcare analytics, claims research, observational studies, and evidence consulting through extensive US data assets.
Evidence production that couples healthcare-linked data integration with protocol-driven cohort build and validation work products.
Optum is a real-world evidence services provider built around large-scale healthcare datasets and end-to-end evidence workflows for observational research and analytics. Its delivery model emphasizes integration of administrative claims and EHR-linked sources, then analysis support that maps study requirements to reproducible outputs.
Optum also supports automation around cohort build, data cleaning, and iterative study refinement for sponsors that need consistent execution across multiple protocols. Governance support shows up in role-based access practices and audit-ready documentation used during evidence production.
- +Deep access to healthcare-linked datasets used for cohort and utilization evidence
- +Strong operational workflows for study build, validation, and iterative protocol refinement
- +Automation focus for repeatable analysis runs across multiple protocols
- +Governance artifacts for sponsor review tied to execution steps
- –Integration depth can increase onboarding effort for sponsors with unique data constraints
- –Automation and reporting breadth may lag specialist boutique workflows
- –RBAC and audit controls are effective but require early alignment on responsibilities
- –Turnaround depends on data access timing and agreed transformation scopes
Healthcare compliance teams
Audit records and coding decisions
Traceable corrective findings
Hospitals and multi-site teams
Coordinate managed coding for claims
Claims-ready structured data
Show 2 more scenarios
Registry and quality teams
Abstract structured clinical data
Consistent structured study data
Abstracts structured information across sources using defined protocols to support real world evidence quality workflows.
Multi-site practice operations
Standardize delivery across locations
Standardized operational delivery
Coordinates operations across sites so real world evidence studies and reporting run with consistent procedures and documentation.
Best for: Fits when sponsors need governed, repeatable RWE production using claims plus clinical sources under tight execution controls.
Merative
enterprise_vendorProvides healthcare data, outcomes research, clinical evidence, and population health analytics services.
Project delivery includes structured provenance and dataset build controls tied to sponsor-facing study outputs.
Merative’s delivery model fits teams that require hands-on project execution rather than only standalone analytics tools. The provider supports study planning, dataset construction, and analysis with attention to data lineage and quality checks that enable audit-ready documentation. Integration depth is a core theme because Merative works across multiple healthcare data sources and study designs, including retrospective cohort work and external control approaches.
A key tradeoff is that Merative’s strongest value comes with structured governance and defined data scope, which can slow timelines when upstream requirements are still changing. Merative works best for sponsors that already know the target question and want a staffed execution path for end-to-end RWE delivery, including study build, confounding controls, and final evidence synthesis.
- +End-to-end observational study execution with documented data lineage practices
- +Cross-source RWE support across claims, EHR-derived data, and linked study populations
- +Governed delivery model that fits sponsor-facing documentation needs
- +Operational experience with causal and confounding control methods
- –Timeline sensitivity when data scope and study protocol are still in flux
- –Less suitable for teams seeking self-serve analytics-only delivery
- –Requires strong sponsor inputs on endpoints and cohort definitions
- –May need additional partner coordination for very niche data sources
Biopharma RWE program leads
Retrospective cohort evidence for treatment patterns
Evidence package ready for decisions
Regulated evidence stakeholders
External control approaches for comparative claims
Comparable cohorts with clear assumptions
Show 2 more scenarios
Health economics teams
Healthcare utilization and cost characterization
Actionable utilization insights
Merative builds analysis-ready datasets to quantify utilization trajectories and evidence-driven utilization patterns.
EHR data strategy owners
EHR-derived outcomes with linkage
Consistent cohorts across sources
Merative helps translate source data to study-ready cohorts with controlled lineage and quality checks.
Best for: Fits when sponsors need staffed RWE delivery with strong provenance, linkage, and governed outputs.
Analysis Group
specialistConducts observational studies, causal inference, health economics, and policy analysis for healthcare clients.
Single engagement ownership from cohort build through causal sensitivity analysis supports consistent estimand interpretation.
Analysis Group’s service delivery centers on observational study workflows where cohort construction, confounding control, and results interpretation are handled within a single engagement team. The firm commonly supports comparative effectiveness work by selecting analytic strategies that match the data generating process and the target estimand. Documentation output is geared toward decision use, with attention to variable definitions and reproducible analysis steps rather than slide-level summaries.
- +Study teams integrate cohort definition and analysis within one execution line
- +Sensitivity planning is structured around decision-ready evidentiary assumptions
- +Strong support for confounding control choices tied to estimand intent
- +Clear documentation for variable definitions and analytic steps
- –Early data feasibility alignment is required for fast turnaround on complex estimands
- –API-based automation is not the primary delivery surface for engagements
- –Data access timelines can dominate schedule in multi-source studies
Biopharma medical affairs
Comparative effectiveness from observational claims
Decision-ready comparative results
Pharmacovigilance analytics
Treatment patterns and outcomes
Clinically interpretable utilization shifts
Show 1 more scenario
Regulatory evidence teams
External control arm planning
Consistent comparator construction
Translates evidentiary questions into eligibility logic and comparison framework using observational methods.
Best for: Fits when a sponsor needs end-to-end RWE execution with tight alignment to estimands and sensitivity plans.
Parexel
enterprise_vendorSupports RWE strategy, observational studies, patient registries, and post-launch evidence generation.
Evidence workflow that ties analytic plans and outcomes to clinical-style study deliverables for regulator-facing narratives.
Parexel’s real-world evidence work is delivered with the same operational disciplines used in global clinical trials, including documented study workflows, standardized deliverables, and structured cross-functional handoffs. Delivery commonly includes extraction and harmonization from multiple source types, analytic planning, outcome definition, and defensible reporting for healthcare utilization and comparative effectiveness questions. Fit signals are strongest for buyers that already have clinical and evidence documentation requirements and want an embedded partner to coordinate analysis workstreams end to end.
- +Clinical-trial style execution for evidence narratives across complex stakeholders
- +Structured evidence deliverables that map analytics to protocol concepts
- +Multi-source observational study workflow coverage for end-to-end projects
- +Clear operational ownership across study design, data work, and reporting
- –Less suited for short turnaround exploratory analytics
- –Integration and governance requirements can increase coordination overhead
- –Advanced study customization may depend on analyst-led scoping calls
- –Automation depth depends on specific ingestion and analytics approach
Pharmacovigilance and evidence teams
Evidence generation for safety and utilization
Consistent evidence package for review
Medical affairs leadership
Comparative effectiveness with external comparators
Defensible comparisons for publications
Show 1 more scenario
Clinical operations directors
Retrospective protocol-aligned real-world study
Protocol-consistent retrospective analysis
Translates study intent into data acquisition, analytic definition, and deliverable mapping.
Best for: Fits when clinical evidence teams need end-to-end RWE execution with strong governance and documentation.
PHASTAR
specialistDelivers biostatistics, statistical programming, epidemiology, and RWE analysis for clinical and post-market research.
External control arm construction paired with systematic confounding control and client-facing study artifacts.
PHASTAR is a real-world evidence services provider that is differentiated by end-to-end study delivery tied to its controlled analysis workflow. It supports RWD to RWE projects that include observational study execution and external control arm construction using data preparation through analysis.
- +End-to-end study delivery reduces handoff gaps between data prep and analysis
- +Clear focus on external control arm and confounding control methods for observational work
- +Method-focused documentation supports client review and study governance cycles
- +Operational experience suits multi-workstream RWE timelines with defined milestones
- –Automation depth depends on engagement design and expected client responsibilities
- –RWE output quality is tied to upfront protocol and data access planning discipline
- –Less suited for fully DIY teams that need only software components or templates
- –Throughput can constrain projects that require frequent mid-study scope changes
Observational study teams
Run RWD to external control arms
Study-ready real world evidence
Regulated evidence review teams
Document fit-for-purpose methods
Review-ready study artifacts
Show 1 more scenario
Methods-first biostatistics teams
Select causal approach within delivery workflow
Reproducible evidence package
Delivers controlled analysis artifacts for observational real world evidence work that needs reproducible method records.
Best for: Fits when sponsor teams need managed RWE delivery for observational studies and external control arms.
Lumanity
specialistDelivers RWE, HEOR, epidemiology, market access, and medical strategy services for life sciences organizations.
Target trial emulation support integrated into dataset preparation and analysis execution.
Lumanity is a real-world evidence service provider that supports end-to-end study delivery for observational research and pragmatic clinical trial work. The core capability is translating client objectives into study-ready datasets and analysis plans that can include target trial style emulation and rigorous missing-data handling.
- +End-to-end delivery links study design and statistical implementation tightly
- +Clear documentation artifacts for observational evidence workflows
- +Method support for target trial emulation style causal comparisons
- +Quality checks that cover missing-data assessment before final estimates
- –Onboarding depends on timely specification of study endpoints and inclusion criteria
- –Advanced causal workflows require disciplined governance from the study team
HEOR and outcomes teams
Deliver observational real world evidence
Documented comparative evidence
Evidence strategy and market access
Map gaps to executable studies
Executable evidence plan
Show 2 more scenarios
Causal inference biostatistics teams
Apply target trial emulation
Structured causal comparisons
Uses target trial emulation methods to support causal real world evidence comparisons from real world data.
Evidence teams with limited operations
Manage execution end to analysis
Managed study delivery
Coordinates study setup, operational delivery, and analytics so real world evidence progress reaches reporting outputs.
Best for: Fits when teams need managed RWE delivery with causal design support and documented analysis implementation.
ICON
enterprise_vendorProvides epidemiology, RWE studies, patient registries, and post-marketing research for pharmaceutical and biotechnology companies.
External control arm delivery with documented comparability planning and analysis artifacts for sponsor review.
ICON delivers real-world evidence programs with an operations model built around study execution teams and data-to-analysis workflows. The capability focus centers on protocol-driven observational studies, external control arms, and evidence generation using multiple data sources such as EHR and claims.
- +Execution teams handle end-to-end observational study workflows
- +Supports external control arm designs for comparative effectiveness
- +Data quality checks are integrated into evidence timelines
- +Cross-source analytics fit studies combining claims and EHR inputs
- –Requires tight sponsor alignment on endpoints and comparability assumptions
- –API and automation surface is not emphasized for self-serve data prep
- –Turnaround depends heavily on data access and source readiness
- –Governance artifacts increase workload for teams needing lightweight workflows
Regulatory and clinical development teams
Integrate protocols and safety narratives
Traceable submission materials
Clinical statisticians
Produce review-ready statistical outputs
Review-ready analyses
Show 2 more scenarios
Pharmaceutical developers
Coordinate evidence-focused study execution
Consistent study reporting
Manages study logistics and reporting workflows that produce submission-oriented study outputs relevant to real world evidence.
Sponsor laboratory operations teams
Run specimen chain of custody workflows
Controlled lab operations
Oversees laboratory procedures and data capture so lab results transfer correctly into real world evidence reporting.
Best for: Fits when sponsors need managed RWE study execution tied to comparative design and evidence-grade outputs.
Trinity Life Sciences
specialistProvides RWE, HEOR, market access, commercial analytics, and strategic consulting for biopharma.
Operational delivery that couples cohort build with packaged study artifacts for downstream observational analyses.
Trinity Life Sciences delivers real-world evidence services with a focus on observational study execution rather than just data access. Core work centers on turning available healthcare records and derived datasets into study-ready cohorts, with documentation oriented toward downstream review.
- +End-to-end observational study support from cohort creation to evidence deliverables
- +Clear operational ownership for study timelines and production artifacts
- +Data curation steps designed to make downstream analysis reproducible
- +Works well when internal teams need augmentation for RWE execution
- –Limited transparency into automation depth and API-style integration surface
- –Requires more vendor coordination when inputs depend on strict provenance handling
- –Process-fit matters more than self-serve tooling for analysts
- –Narrower fit for teams seeking highly configurable workflows
Oncology analytics teams
Prepare de-identified oncology cohorts
Traceable analytic extracts
Biotech translational teams
Plan evidence across workstreams
Decision-ready evidence plan
Show 2 more scenarios
Market access and health economics
Translate evidence into access narratives
Evidence-informed access narrative
Maps real world evidence to stakeholders and coverage inputs to support evidence-informed reimbursement planning.
Clinical development and regulatory teams
Define study structure and endpoints
Protocol and development documents
Advises on observational study structure, endpoints, and feasibility to align real world evidence execution planning.
Best for: Fits when sponsors need managed observational study execution and consistent deliverables for review timelines.
Costello Medical
specialistProvides RWE, HEOR, systematic reviews, epidemiology, and medical communications for life sciences clients.
Evidence-ready study documentation that traces case definitions, data quality checks, and analysis decisions into final outputs.
Costello Medical delivers real-world evidence studies that translate clinical questions into observational study execution and evidence-ready outputs. It is distinguished by end-to-end hands-on support across protocol development, cohort design, and analytical work products intended for external stakeholders.
- +Service-led study execution with documented cohort and analysis decisions
- +Clear separation of study design artifacts from statistical deliverables
- +Good fit for evidence packages that require cross-functional stakeholder alignment
- +Strong focus on data quality planning and missingness-aware interpretation
- –Less suitable for teams seeking self-serve automation and rapid configuration
- –Requires governance discipline to keep protocol, analysis, and output versions aligned
- –Automation and API surface are not a primary product emphasis
- –Turnaround depends on study complexity and integration scope
Clinical development teams
Execute protocol to cohort design
Execution-ready RWE outputs
Evidence generation teams
Create reproducible analysis workflows
Reproducible evidence package
Show 1 more scenario
Regulated stakeholder reporting
Guide interpretation for results
Documented interpretation
Supports real world evidence interpretation with documented artifacts that facilitate consistent external stakeholder review.
Best for: Fits when stakeholders need tightly documented RWE execution with controlled design-to-results traceability.
Conclusion
After evaluating 10 real world evidence, Certara stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.
Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.
Frequently Asked Questions About Real World Evidence
How do Analysis Group and ICON manage study design choices when the estimand changes after data exploration?
Which providers handle external control arm construction with documented confounding control artifacts?
What breaks first when a sponsor expects claims data and EHR-derived sources to behave like a single integrated dataset?
How does Merative’s data provenance practice affect regulator-facing evidence documentation compared with parexel’s governance model?
When does Certara’s programmatic dataset production matter more than project-by-project manual programming?
How do Optum and Trinity Life Sciences differ in onboarding focus for observational study throughput?
Which providers integrate target trial emulation support into the same delivery chain that builds datasets and implements analyses?
How do Parexel and Costello Medical handle traceability from case definitions to analytic decisions?
What admin controls and audit artifacts are typically required for secure evidence production across stakeholder access needs?
When do sponsors need deeper extensibility around multi-source data ingestion versus tighter hands-on guidance on decision points?
Tools reviewed
Primary sources checked during evaluation.
Referenced in the comparison table and product reviews above.
How to Choose the Right Real World Evidence
We separate options by whether their real world evidence exports stay traceable from question to dataset. Look for clear publication support in the workflow, not just a list of methods.
Publication traceability to underlying data
Why it matters
For real world evidence, publication traceability matters because you need to see exactly which dataset and transformation produced each claim figure. Without it, you can’t judge whether results reflect your target question.
How to check
Pick a sample figure from the page. Then ask the product to show where that figure’s source data came from, including any preprocessing or filtering steps.
Figure-to-claim coverage in extraction
Why it matters
Real world evidence hinges on figures and the statements that surround them. If extraction misses the figure that supports a conclusion, you’ll get confident-looking gaps.
How to check
During a demo, select one real world evidence passage and request the corresponding figure(s). Confirm the tool also captures the adjacent claim sentence(s) that interpret the figure.
Dataset provisioning for reproducible pull
Why it matters
Reproducibility affects how much you can reuse real world evidence outputs across reviews. Good provisioning reduces the guesswork between “what the publication says” and “what you can re-check.”
How to check
Ask the vendor to generate a reproducible dataset pull from a provided prompt. Then verify it includes the exact filters/time window and a way to re-run the same pull.
Data quality notes attached to outputs
Why it matters
For real world evidence, data quality notes affect whether you can trust comparisons across studies. If quality constraints are missing, you’ll struggle when results conflict.
How to check
Request a sample output and inspect whether it includes explicit quality checks or limitations tied to the extracted dataset and figures. Ask what triggers those notes and whether they can be turned on/off.
Update frequency controls for evidence pages
Why it matters
Real world evidence grows stale when sources or figures change. Update controls let us refresh extracted evidence without rebuilding everything from scratch.
How to check
Ask how the tool detects changes to the underlying publication page and when it refreshes. Then show a workflow that keeps prior outputs linked to the new version.
Red flags
- Figures are shown but the tool can’t point to the underlying dataset pull steps.
- Outputs lack any quality or limitation notes tied to the extracted evidence.
- Refreshing a page breaks traceability between the old and new figures.
Fit by situation
- If we repeatedly re-check the same real world evidence claims across projects, prioritize Publication traceability to underlying data.
- If we need the figure and the interpretation sentence to travel together for reviews, prioritize Figure-to-claim coverage in extraction.
- If we expect publications to change and want refreshable evidence outputs, prioritize Update frequency controls for evidence pages.
Funding and competing interests
This study was co-funded by several of the vendors assessed in it. No single vendor funded it. Funders could propose the market studied.
They had no role in selecting vendors, setting or weighting criteria, analysing data or drawing conclusions, and they received the same factual-accuracy check as every other vendor assessed.
Market definition, inclusion rules and criteria weights were fixed by an editor before research began and did not change afterwards. Editorial process →
- Data Science AnalyticsTop 10 Best Real World Data Services of 2026
- Science ResearchTop 10 Best Evidence Collection Software of 2026
- Business FinanceTop 10 Best Real World Software of 2026
- Data Science AnalyticsTop 10 Best Real Estate Data Services of 2026
- Science ResearchTop 10 Best Health Care Research Services of 2026
Keep exploring
Comparing two specific tools?
Software Alternatives
See head-to-head software comparisons with feature breakdowns, pricing, and our recommendation for each use case.
Explore software alternatives→In this category
Science Research alternatives
See side-by-side comparisons of science research tools and pick the right one for your stack.
Compare science research tools→